1. Introduction
===============

Acute cerebral infarction (ACI) is common type of severe neurological disease,^\[[@R1]--[@R4]\]^ which is characterized by neurological deficit syndrome caused by a sudden blood flow supply interruption to brain.^\[[@R5]--[@R8]\]^ Previous studies reported that patients with ACI have high incidence, disability, mortality, and recurrence rate,^\[[@R9]--[@R12]\]^ which result in tremendous impact of quality of life in such population.^\[[@R13]--[@R16]\]^ A variety of risk factors are reported to have close association with ACI, such as hypertension, smoking, ischemic heart disease, hyperlipidaemia, diabetes mellitus, carotid artery stenosis, atrial fibrillation, obesity, family history of stroke, physical inactivity and non-alcoholic fatty liver (NAFL).^\[[@R6],[@R17]--[@R22]\]^ Several studies have reported that there is association between NAFL and ACI.^\[[@R22]--[@R27]\]^ However, there is not systematic review focusing on this topic. Thus, this study aims to systematically investigate the association between NAFL and ACI.

2. Methods
==========

2.1. Objective
--------------

This study will aim to explore the association between NAFL and ACI systematically and comprehensively.

2.2. Study registration
-----------------------

This study has been registered on INPLASY202040102. It has been reported according to the guideline of preferred reporting items for systematic reviews and meta-analysis protocol statement.^\[[@R28]\]^

2.3. Inclusion criteria for study selection
-------------------------------------------

### 2.3.1. Type of studies

All potential case-controlled studies will be included, which identified the association between NAFL and ACI, regardless language and publication status limitations.

### 2.3.2. Type of participants

In this study, the reports of all subjects with NAFL and ACI, or normal healthy participants will be included, regardless race, age, and sex.

### 2.3.3. Type of exposures

All subjects in the experimental group had NAFL and ACI.

All participants in the control group were healthy without NAFL and ACI.

### 2.3.4. Type of outcome measurements

Outcomes are severity of ACI (measured by National Institutes of Health Stroke Scale, or other scales), serum levels of glucose, triglycerides, total cholesterol, low density lipoprotein cholesterol, high-density lipoprotein cholesterol, creatinine, serum alanine aminotransferase, aspartate aminotransferase, and uric acid.

2.4. Data sources and search strategy
-------------------------------------

### 2.4.1. Electronic searches

This study will comprehensively search electronic databases (MEDLINE, EMBASE, Cochrane Library, Scopus, Web of Science, WANGFANG, and China National Knowledge Infrastructure) from their sources to the March 1, 2020 without limitations related to the language and publication status. We have created search strategy sample for MEDLINE (Table [1](#T1){ref-type="table"}), and have adapted similar search strategies for other electronic databases.

###### 

Search strategy for MEDLINE.
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### 2.4.2. Other resources

We will identify other sources, including conference abstracts and reference lists of included trials.

2.5. Data collection and analysis
---------------------------------

### 2.5.1. Selection of studies

Two review authors will independently examine all searched citations, and all duplicates will be removed. Titles/abstracts of all potential studies will be screened to exclude any irrelevant studies. Full papers of remaining trials will be carefully read against all inclusion criteria. Any disagreements will be arbitrated through discussion with the help of a third review author. The process of study selection will be presented in a PRISMA flow diagram.

### 2.5.2. Data collection and management

Two review authors will independently collect data from included articles. Any discrepancies between 2 review authors will be solved through discussion with a third review author. We will collect study title, first author, year of publication, location, participant characteristics (such as age, gender, severity of NAFL and ACI), outcomes, results, conclusions, and conflict of interest.

### 2.5.3. Dealing with missing data

Any insufficient or missing data will be obtained from original study authors. We will analyze available data using an intention-to-treat analysis if we cannot receive any reply.

2.6. Study quality assessment
-----------------------------

Study quality of included case-controlled studies will be examined by 2 independent review authors using Newcastle-Ottawa Scale.^\[[@R29]\]^ Divisions between two review authors will be settled by discussion with a third review author.

2.7. Statistical analysis
-------------------------

### 2.7.1. Data synthesis

This study will employ RevMan V.5.3 to pool and analyze all extracted outcome data. We will exploit dichotomous data by risk ratio and 95% confidence intervals (CIs). We will express continuous data by weighted mean difference or standardized mean difference and 95% CIs. We will use *I*^2^ test to check heterogeneity. The values of *I*^2^ are defined as follows: *I*^2^ ≤ 50% shows homogeneity, we will use a fixed-effects model, while *I*^2^ \> 50% suggests apparent heterogeneity, and we will utilize a random-effects model. We will carry out a meta-analysis if homogeneity is examined. Otherwise, we will perform a subgroup analysis to investigate the possible sources of distinct heterogeneity.

### 2.7.2. Subgroup analysis

If possible, a subgroup analysis will be performed according to the study characteristics, study quality, and outcomes.

### 2.7.3. Sensitivity analysis

We will carry out a sensitivity analysis to check the robustness of study results by removing the low quality studies.

### 2.7.4. Reporting bias

If over 10 studies are included, we will check reporting bias using a funnel plot and an Egger regression test.^\[[@R30]\]^

2.8. Ethics and dissemination
-----------------------------

This study will only collect data from published studies, thus, no research ethic is needed.

We will submit this study on a peer-reviewed journal or a related conference meeting.

3. Discussion
=============

To the best of our knowledge, this is the first study to investigate the association between NAFL and ACI. It will systematically and comprehensively search electronic databases, and other literature sources to avoid missing potential studies. This study will summarize the most recent eligible studies of the association between NAFL and ACI. The findings of this study will provide evidence to judge the association between NAFL and ACI, which may benefit for the clinical practice and future studies.
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